


Sitafloracin

Chemical Properties

CAS No. :	127254-12-0
Formula:	C ₁₉ H ₁₈ ClF ₂ N ₃ O ₃
Molecular Weight:	409.81
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Sitafloracin (Sitafloracin anhydrous) is an orally active fluoroquinolone antibiotic with broad-spectrum antimicrobial activity. Sitafloracin has been used in the study of respiratory tract infections and urinary tract infections.
Targets(IC50)	Antibacterial, Antibiotic
In vitro	Sitafloracin (DU6859a) demonstrates potent antibacterial activity, with MIC values of 0.03 mg/L for quinolone-susceptible strains of Streptococcus pneumoniae EG 00093 and EG 00218, respectively [1].
In vivo	In BALB/c female mice, Sitafloracin (12.5, 25, 50, and 100 mg/kg; oral gavage; once daily for 4 weeks) inhibits the growth of Mycobacterium ulcerans and the cells of M. ulcerans[2].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4402 mL	12.2008 mL	24.4016 mL
5 mM	0.488 mL	2.4402 mL	4.8803 mL
10 mM	0.244 mL	1.2201 mL	2.4402 mL
50 mM	0.0488 mL	0.244 mL	0.488 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Okumura R, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant *Streptococcus pneumoniae*. *J Antimicrob Chemother*. 2008 Jul;62(1):98-104.
- Kong Y, Geng Z, Jiang G, et al. Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, flaxloxacil, and delafloxacin against *Mycobacterium tuberculosis* strains isolated in China. *Heliyon*. 2023
- Doelman T A, Adriaens N, Westerhuis B M, et al. Phenotypic antibiotic resistance of *Mycoplasma genitalium* and its variation between different macrolide resistance-associated mutations. *Journal of Antimicrobial Chemotherapy*. 2024: dkae430.
- Dhople AM, et al. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against *Mycobacterium ulcerans* infection in mice. *J Chemother*. 2003 Feb;15(1):47-52.
- Nakajima T, Okui T, Ito H, Nakajima M, Honda T, Shimada Y, Tabeta K, Akazawa K, Yamazaki K. Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy. *Antimicrob Agents Chemother*. 2016 Jan 4;60(3):1779-87. doi: 10.1128/AAC.02575-15. PubMed PMID: 26729495; PubMed Central PMCID: PMC4775917.
- Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Kanai T. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for *Helicobacter pylori* Strains Containing the gyrA Mutation. *Helicobacter*. 2016 Aug;21(4):286-94. doi: 10.1111/hel.12286. Epub 2015 Nov 27. PubMed PMID: 26612407.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481